<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The recent studies indicated that the epithelial cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule E-cadherin is a well-recognized molecule that is important in cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>To further investigate the molecular basis of this notion, we used small-interfering <z:chebi fb="40" ids="33697">RNA</z:chebi> to inhibit E-cadherin function and found that loss of E-cadherin promoted <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> cell growth, invasion and drug resistance through induction of Î²-catenin nuclear translocation and epithelial-to-mesenchymal transition </plain></SENT>
<SENT sid="2" pm="."><plain>Further analysis of E-cadherin expression with clinicopathologic parameters showed that E-cadherin expression decreased in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> patients who developed <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> (P = 0.043) </plain></SENT>
<SENT sid="3" pm="."><plain>These findings indicate that E-cadherin loss in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> contributes to progression and metastatic dissemination </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, E-cadherin can act as a central modulator of the cell biological phenotypes and a potential prognostic marker in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> </plain></SENT>
</text></document>